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CSN6 is one subunit of the constitutive photomorphogenesis 9 (COP9) signalosome (CSN), which is an evolutionarily
conserved multiprotein complex found in plants and animals and originally described as a repressor of light-dependent
growth and transcription in Arabidopsis. CSN is homologous to the 19S lid subcomplex of the 26S proteasome, thus it
has been postulated to be a regulator of the ubiquitin-proteasome pathway. In mammalian cells, it consists of eight
subunits (CSN1-CSN8). Among the CSN subunits, CSN5 and CSN6 are the only two that each contains an MPN (Mpr1p
and Pad1p N-terminal) domain. The deneddylating activity of an MPN domain toward cullin-RING ubiquitin ligases (CRL)
may coordinate CRL-mediated ubiquitination activity. More and more studies about CSN6 are emerging, and its
overexpression is found in many types of cancers. Evidence has shown that CSN6 is a molecule platform between
protein degradation and signal transduction. Here, we provide a summary of human CSN6, especially its roles in
cancer, hoping that it can lay the groundwork for cancer prevention or therapy.
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The COP9 signalosome, generally named CSN, is an
evolutionarily conserved multiprotein complex existing
in all eukaryotes. It consists of eight subunits termed
CSN1-CSN8 [1]. Among the CSN subunits, CSN6 and
CSN5 are the only two subunits that each share an
MPN (Mpr1p and Pad1p N-terminal) domain, while
other subunits contain a PCI domain, which may serve
as a structure scaffold in the assembly of the COP9 sig-
nalosome [2-4].
The complex was originally described as a repressor of
light-dependent growth in Arabidopsis by Deng and his
collaborators [5]. CSN has diverse functions in cellular
and developmental processes, including cell cycle control,
signal transduction, transcriptional activation [6,7] and
tumorigenesis [8,9]. The most and best studied function is
regulation of ubiquitin-mediated protein degradation
[10-13]. The function is fulfilled by removal of Nedd8/
Rub1 (an ubiquitin-like molecule) from the cullin subunit
of cullin-containing E3 ligases. And the deneddylation* Correspondence: dspei@xzmc.edu.cn; jnzheng@xzmc.edu.cn
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stated.activity toward cullins is necessary for maintaining the sta-
bility and the sustained activity of cullin-RING E3 ligases
(CRLs) in vivo, allowing the ligases to polyubiquitinate
a large number of substrates that are targeted by the
ubiquitin-proteasome system [14-17]. Since many key
oncogene and tumor suppressor products such as p27
[18], c-Jun [19], p53 [8,20,21], COP1 [22] and 14-3-3σ
[22] are degraded via the ubiquitin-proteasome pathway,
it is conceivable that COP9 plays a significant role in
cancer.
As a subunit of COP9 signalosome complex, CSN6 is
found to be overexpressed in many types of cancers
[8,23], linking it to oncogenic activity. Therefore, in this
review, we provide an overview of the role of CSN6 in
cancer and summarize recent findings that highlight the
novel roles of CSN6 in cellular and developmental pro-
cesses, suggesting that CSN6 is a promising therapeutic
target in combating human cancers.CSN6 plays an important role in structural integrity of the
CSN complex
The CSN is ~450 kDa in mass and comprises eight core
subunits called CSN1–CSN8, in order of descending
subunit size [24]. Then, how is this important complex
organized structurally?Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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symmetrical modules, CSN1/2/3/8 and CSN4/5/6/7, con-
nected by interactions between CSN1 and CSN6 [25]. As
mentioned above, CSN6 and CSN5 are the only two
subunits that each share an MPN (Mpr1p and Pad1p
N-terminal) domain. Although CSN6 and CSN5 both
contain the MPN domain, evidence has revealed that
there are two types of MPN domains: one, like CSN5 with
JAMM (Jab1/MPN/Mov34) motif, has the metallopro-
tease activity while another, the same as CSN6 without
JAMM motif, has no related isopeptidase activity, which is
probably involved in protein–protein interaction and
in protein stability [26]. In fact, CSN6 contains an
N-terminal MPN domain and a newly identified S6CD
domain in the carboxyl half of the protein [27]. The MPN
domain is responsible for the interaction with CSN5, and
the S6CD-containing C-terminal half of CSN6 is in asso-
ciation with CSN4 and CSN7, suggesting that CSN6 is a
core protein in the CSN4/5/6/7 subcomplex [28]. More-
over, earlier genetic studies in Arabidopsis showed that
complete depletion of CSN6 resulted in loss of the entire
CSN complex [29]. Therefore, CSN6 is essential for CSN
assembly.
CSN6 is involved in proteasome-mediated protein
degradation
As mentioned above, COP9 coordinates CRL-mediated
ubiquitination activity through its associated dened-
dylation activity toward the cullin subunit of cullin-
containing E3 ligases. The deneddylation activity localizes
to the JAMM (JAB1/MPN/Mov34) motif of CSN5 [30].
However, CSN5 alone has no metalloprotease activity un-
less it is associated with other subunits. Thus the dened-
dylation activity also requires the integrity of the CSN
complex, which needs CSN6. Moreover, it has been shown
that CSN6 makes a contribution to the binding of CSN
and E3 ligases [30,31]. Recent study further demonstrates
that the C-terminal region of CSN6 is necessary and suffi-
cient for CSN complex integrity and recruitment of cullins
to the CSN complex [27]. Taken together, CSN6 plays a
pivotal role in proteasome-mediated protein degradation
via regulating E3 ligases such as MDM2 [8] and COP1
[22].
Roles of CSN6 in tumor
CSN6 is overexpressed in cancer
The human cancer patient transcriptomic data sets from
Oncomine and Gene Expression Omnibus analyzed using
Oncomine analysis tools and Nexus expression 2.0 reveal
that many types of cancer have CSN6 overexpression,
such as glioblastoma, breast cancer, myeloma, leukemia
[23]. Zhao et al [8]. used the System for Integrative
Genomic Microarray Analysis (SIGMA [32]) to evaluate
genetic loss or gain of CSN6 (located at 7q22.1) using datafrom the British Columbia Cancer Agency Research
(BCCRC) SMRT arrays, and found that a substantial per-
centage of samples (breast cancer cell lines and other
types of cancer cells) had amplification of the CSN6
genomic region. And then they used quantitative PCR to
confirm the gene amplification of CSN6 in breast cancer
samples experimentally. Amplification of CSN6 was de-
tected in a high percentage of breast cancer samples, and
there was a positive correlation between CSN6 gene copy
number and tumor size. Also, by comparing malignant
follicular thyroid carcinomas with benign thyroid lesions
(follicular adenomas, adenomatous nodules, and multi-
nodular goiters) and normal thyroid tissue, they found
that the carcinomas expressed higher levels of CSN6 than
did benign lesions and tissues. These results suggest that
CSN6 is overexpressed in cancer and is not restricted to a
few specific types or cases of cancer.
Physiological significance of CSN6 overexpression in cancer
CSN6 is overexpressed in many types of cancer [8,23],
linking it to oncogenic activity. However, detailed mecha-
nisms through which CSN6 contributes toward carcino-
genesis/tumor development remain unclear. Previously,
human CSN6 was identified to interact with the human
immunodeficiency virus 1 accessory protein Vpr (also
called hVIP for Vpr interactive protein) and found to be
involved in the G2/M phase transition of the cell cycle
and cell proliferation [33]. Recently, more and more stud-
ies about CSN6 focus on the signaling pathways in which
it is involved during carcinogenesis/tumor progression.
CSN6-MDM2-p53 axis
As a RING domain-containing E3 ubiquitin ligase,
MDM2 can ubiquitin tumor suppressor p53 at several
lysine residues, which causes p53 degradation. It can also
degrade itself by autoubiquitination [34,35]. Overex-
pression of MDM2 is found in a wide variety of human
tumors [36]. Zhao et al [8]. studied the expression of
MDM2 and CSN6 in matched normal and cancerous
breast tissues, and found that CSN6 was concomitantly
overexpressed with MDM2 in human breast cancer tis-
sues. Mechanism studies indicated that CSN6 prevented
MDM2 autoubiquitination at lysine 364, resulting in
stabilization of MDM2 and degradation of p53. Moreover,
CSN6 couldn’t induce p53 degradation in Mdm2-null
mouse embryonic fibroblasts, suggesting that CSN6-
mediated degradation of p53 is MDM2 dependent. Mice
in which CSN6 was deleted died early in embryogenesis,
which could be rescued by concomitant loss of p53.
Mice heterozygous for CSN6 (CSN6+/−) exposed to
high doses of γ-irradiation (IR) showed more apoptosis
due to an increased p53 activity. And loss of expression
of CSN6 could attenuate carcinogenesis/tumor progres-
sion in response to DNA damage, which is known to be
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oncogene with positive activity toward MDM2 and plays a
significant role in DNA damage-associated apoptosis and
tumorigenesis through MDM2-p53 signaling pathway.
CSN6-COP1 axis
As another E3 ubiquitin ligase for p53, COP1 targets p53
for degradation by ubiquitin-dependent proteasome sys-
tem, independently of MDM2 or Pirh2, which are known
to interact with and negatively regulate p53, thereby main-
taining p53 at low levels in unstressed cells and inhibiting
p53-dependent transcription and apoptosis [37]. 14-3-3σ
is a gene upregulated by p53 and has a positive feedback
effect on p53 in response to DNA damage. It has been
found to be frequently lost or decreased in various human
cancers and functions as a potential tumor suppressor
[38-40]. Recently, CSN6 was found to interact with COP1
and be involved in 14-3-3σ ubiquitin-mediated degra-
dation [22]. Co-IP shows that CSN6 associates with COP1
endogenously and in vivo binding assay confirms that
CSN6 directly binds to COP1 [22]. CSN6 stabilizes COP1
through reducing COP1 self-ubiquitination and decelera-
ting COP1’s turnover rate [22]. The CSN6-COP1 axis has
following physiological significance possibly: (1) CSN6
stabilizing COP1 directly enhances COP1-mediated p53
ubiquitination and degradation. (2) CSN6-COP1 axis
causes 14-3-3σ degradation, which on the one hand, can
block 14-3-3σ’s positive effect on p53 stability, on the
other hand, activates Akt and promotes Akt-mediated cell
survival.
CSN6-p57 axis
Recently, it is shown that CDK inhibitor (CDI) p57kip2 is a
new target of CSN6 [41]. The p57Kip2 protein (abbreviated
as p57) is a member of p21Cip1/p27Kip1 CDI family,
sharing similar sequence with p27Kip1, also known as
CDKN1C. Its overexpression causes a complete cell cycle
arrest in G1 phase [42]. Decreased expression of p57 has
been found in many types of cancer, including bladder
carcinoma, gastric cancer and pancreatic cancer [43].
Stabilization of p57 is essential for the maintenance of its
tumor suppressor function. Therefore, deregulation of
proteins that affect p57 protein stability is expected to
have an impact on human tumorigenesis. It’s well known
that degradation of p57 is dependent on ubiquitylation,
which is mediated by Skp2, an important component of
Skp1/Cul1/F-box (SCF)-type E3 ubiquitin ligase [44].
Chen et al [41]. found that CSN6 was involved in p57
downregulation and increased the ubiquitination level of
p57 in a dose-dependent manner. Mechanism studies
show that CSN6 interacts with p57 and Skp2 through its
C-terminal domain, which, in turn, promotes Skp2-
mediated protein ubiquitination of p57, thereby decrea-
sing the steady-state expression of p57. Significantly,CSN6 overexpression antagonized p57-mediated cell pro-
liferation inhibition, G1 arrest and cell transformation
suppression. Moreover, high expression levels of CSN6
and low expression levels of p57 correlated with poor
overall survival in human tumor samples. Thereby, the
CSN6-p57 link will be an important molecular target for
cancer therapy and intervention [41].
HER2-Akt-CSN6 axis
CSN6 plays an important role in protein degradation,
however, the molecular signals in regulating CSN6 acti-
vity are largely unknown. It is well known that HER2-
Akt is critical in regulating p53 activity through MDM2
[45]. Recent study has shown that CSN6 is pivotal in
regulating MDM2 to destabilize p53 [8]. Based on these
studies, Lee’s laboratory further found that HER2-Akt
axis is linked to CSN6 regulation, and that Akt is a posi-
tive regulator of CSN6 [46]. Akt is able to associate with
CSN6 and phosphorylate it at Ser60, which can reduce
the ubiquitin-mediated protein degradation and turnover
rate of CSN6, thereby increasing steady-state expression
of CSN6. Furthermore, Akt’s positive impact on CSN6
overexpression results in p53 degradation, cell trans-
formation and DNA damage [46].
CSN6 cleavage during apoptosis can regulate
CSN-mediated deneddylation
In addition, few studies point out that CSN6 may partici-
pate in apoptosis process. For example, CSN6 can interact
with amino-terminal caspase recruitment domain (CARD)
of Nod1, a cytoplasmic protein that belongs to the Nod/
NLR/CATERPILLER protein family and whose activation
is involved in apoptotic pathways. During Nod1-induced
apoptosis process, CSN6 is cleaved by recombinant cas-
pase 8, suggesting that CSN6 is a direct target of caspase 8
[47]. However, how CSN6 is cleaved and the significance
of CSN6 cleavage is still unclear. Later, in vitro and in vivo
experiments further indicate that CSN6 is cleaved during
apoptosis by activated caspases, most effectively by active
caspase 3. And CSN6 cleavage is followed by cleavage of
Rbx1, a component of CRL, thereby resulting in activation
of CSN-mediated deneddylation and inactivation of CRLs
[48]. These data demonstrate that CSN-mediated dened-
dylation can be regulated by active caspases and that the
CSN6 executes a specific function during the apoptotic
process.
Concluding remarks
In this review, we have discussed the contribution of
CSN6 to COP9 signalosome structurally and functionally,
particularly focusing on roles of CSN6 in carcinogenesis/
tumor development. As a subunit of COP9 signalosome,
the roles of CSN6 in cancer could be linked to its involve-
ment in ubiquitin-mediated protein degradation. However,
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Cullin-RING E3 ligases remain to be fully elucidated.
It has been confirmed that deneddylation activity loca-
lizes to the JAMM (JAB1/MPN/Mov34) motif of CSN5
[30]. Nonetheless, the MPN domain of CSN6 is respon-
sible for protein-protein interaction, while the newly iden-
tified S6CD domain in the carboxyl half of CSN6 is
necessary and sufficient for CSN complex integrity and
recruitment of cullins to the CSN complex [27], which is
needed for deneddylation activity. Therefore, it seems that
CSN6 executing its function is based on its effects on the
whole CSN complex.
Recent findings about CSN6 mainly focus on its in-
volvement in signaling pathways during tumorigenesis.
For example, CSN6 connects HER2-Akt pathway with
MDM2-p53 pathway [49], thereby regulating the expres-
sion of p53, a crucial tumor suppressor well known to
us. In addition, CSN6 can stabilize COP1 and target sub-
strates of COP1, such as 14-3-3σ and p53. Recently, p57,
a new target of CSN6, is found to be regulated by CSN6
through Skp2. However, little is known about its up-
stream regulators. So far, few upstream regulators of
CSN6 have been mentioned. For instance, Akt can posi-
tively regulate CSN6 by phosphorylation. Caspases also
cleave CSN6 during apoptosis. Thus it is necessary to
discover new regulators and targets of CSN6. As for
the phosphorylation event, Akt can phosphorylate CSN6
and MDM2. However, could it regulate other p53 ubi-
quitin ligases, such as COP1, MDMx [50,51], to parti-
cipate in p53 degradation? Is it also regulated by DNA
damage? Could the upregulation of p53 in response to
DNA damage have effect on CSN6 in turn?
In conclusion, CSN6 takes an active part in carcino-
genesis/tumor development, suggesting its oncogene ac-
tivity. Further investigations to understand the functions
of CSN6 and its roles in cancer should be performed, thus
significantly accelerating the development of a novel the-
rapeutic strategy for various types of cancer.
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